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Abstract 
Background: Antifungal drug resistance and few numbers of available drugs limit therapeutic options against fungal 
infections. The present study was designed to discover new antifungal drugs. 
Materials and Methods: This study was carried out in two separate steps, that is, in silico lead identification and in 
vitro assaying of antifungal potential. A structural data file of a ternary complex of fusicuccin (legend), C terminus of 
H
+
-ATPase and 14-3-3 regulatory protein (1o9F.pdb file) was used as a model. Computational screening of a virtual 
3D database of drug-like molecules was performed and selected small molecules, resembling the functional part of the 
ligand performing ligand docking, were tested using ArgusLab (4.0.1). Two lead compounds, 3-Cyclohexan propionic 
acid (CXP) and 4-phenyl butyric acid (PBA) were selected according to their ligation scores. Standard Strains of 
Candida albicans and Saccharomyces cerevisiae were used to measure the antifungal potential of the two identified 
lead compounds against the fungi using micro-well plate dilution assay. 
Results: Ligation scores for CXP and PBA were -9.33744 and -10.7259 kcal/mol, respectively, and MIC and MFC 
of CXP and PBA against the two yeasts were promising. 
Conclusion: The evidence from the present study suggests that CXP and PBA possess potentially antifungals 
properties. 
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Introduction 
Despite traditional approaches to drug discovery, which 
is predicated upon laboratory practices through stepwise 
synthesis and screening methods, rational drug deigning 
using calculating power of a new generation of powerful 
computers affords new opportunities to in silico drug 
designing and evaluation. The rational approaches to drug 
discovery are based upon lead discovery using known 
information with respect to the structure of a drug 
receptor or one of its natural ligands
1
. The information 
may incorporate three-dimensional structure data of 
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protein, ligand, or their combination determined by X-
ray crystallography or nuclear magnetic resonance 
(NMR) spectroscopy, which is usually registered as 
PDB file in easy accessible protein data bank. According 
to the available information, one can search databases 
for structures resembling identified lead and select the 




The lead, which is a small molecule, performs a desired 
biological or pharmacological activity. Structural 
modification of an identified lead is often a prerequisite 
for production of an effective drug. To inhibit or 
accelerate their activities, drugs usually interact with 
target molecules (receptors). Moreover, a lead is directed 
to its target molecule and selected based upon its 
interaction with the target. The lead is proposed 
predicated upon a known ligand with binding specificity 
to its target molecule with a rational design. A lead is 
commonly made by a small part of the ligand with 




The powerful tools of molecular biology have been 
utilized in fungi and plants over the last decade and 
made rapid progress in the molecular basis of the fungal 
and plant proton pumps. The cells are to actively extrude 
protons across the plasma membrane mediated by an 
ATP-driven proton pump. The proton pump (H
+
-
ATPase), which is an integral membrane protein,  keeps 
high rate of identity among plants and fungi; 
nevertheless, the pump in animal cell membrane is 
related to a different protein family
5
. The plasma 
membrane H
+
-ATPase (PMA) of fungi is a single 
polypeptide, which has a molecular mass of 
approximately 100 kDa, comprised of 10 transmembrane 
alpha helices. Both N- and C-terminals of the helices are 
at the cytoplasmic surface of the membrane. H
+
-ATPase 
pumps protons across the plasma membrane control 
membrane potential, intracellular ion concentrations and 
provide the driving force for nutrient uptake by 
consuming ATP as an energy source
6
. Preliminary 
studies into both plant and yeast materials indicated that 
C-terminal region of the molecule exerted an 
autoinhibitory role in its ATPase activity and 
penultimate threonine residue phosphorylation is 
essential for subsequent association of the C-end with 
14-3-3 regulatory proteins and thus for activation of the 
pump. The phosphopeptide end of the molecule occupies 
the central binding groove of 14-3-3 protein. The 
eukaryotic 14-3-3 families of molecules refer to dimeric 
highly conserved regulatory proteins bound to their 
numerous target proteins in a sequence-specific and 
phosphorylation-dependent manner. The 14-3-3 binding 
motif at the C-terminus of the H
+
-ATPase includes the 
amino acid sequences of QQXYpT (948) V
7-9
. 
Fusicoccin (FC), a phytotoxin, is made by the fungus 
Fusicoccin amygdali (figure 1)
10
. Isolated FC exerts 
wilting impact upon higher plants and plasma membrane 
H+-ATPase (PMA) is its molecular target. Preceding 
research demonstrated that FC stabilized the interaction 
between the C-terminus of the plant PMA, and 14-3-3 
proteins, and brout about permanent activation of the 
proton pump and wilting of plants by formation of an 
irreversible stomatal pore
11
. It was suggested that the 
toxin alone binds weakly to 14-3-3 regulatory protein and 
peptide-toxin association mutually hightens the binding 
affinity by 93-fold. The fungal toxin fills a solvent-
exposed cavity in the 14-3-3 complex, and hence 




The formation of an H
+
-ATPase-14-3-3 complex in the 
absence of FC absolutely depends on the phosphorylation 
of penultimate threonine residue (Thr-948), however, 
binding of 14-3-3 in the presence of FC happens 
independent of phosphorylation embodies the C-terminal 
motif YTV. Effectively, substitution of Thr-948 in the 
plant H
+
-ATPase for alanine is lethal inasmuch as this 






The crystal structure of the ternary complex between 14-
3-3 protein, Fusicoccin and a phosphopeptide obtained 
from the C-terminus of the H
+
-ATPase was first 
introduced by Martin Wurtele in 2003. For elucidation of 
the contributory mechanisms to the Fusicoccin action, 
comparisons were drawn between the ternary structure 
and the corresponding binary complexes and showed no 
major conformational change in the protein by 
Fusicoccin; FC fills a cavity in the protein-
phosphopeptide interaction surface and stabilizes this 
interaction
14
. The PMA-binding peptide QSYpTV-COOH 
differs from the binding motifs of a polyoma middle-T 
peptide (RSXpS/TXP) and a library-derived peptide 
(RXXXpS/TXP), the two letters are recognized by all 
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mammalian 14-3-3 isoforms and are not situated at the 
very C-terminal end of the interaction partner
14,15
. 
Antifungal drug resistance and low number of available 
drugs curtail therapeutic options against fungal 
infections. Therefore, further research may be required 
to discover and introduce new antifungal agents. Should 
be plasma membrane H
+
-ATPase a selective target, 
which its structure are quite different between fungal and 
mammalian cells, it can be considered as a promising 
new drug target. The crystal structure of the ternary 
complex between 14-3-3 protein, Fusicoccin and C-
terminus of the pump is accessible through searching 
protein data banks (pdb entry: 1o9F). The present study 
set out to find new lead compounds having antifungal 
property by means of silico methods with required 
structural data. 
Methods 
This study was carried out in two separate steps as 
follows: 1) in silico lead identification 2) assaying the 
antifungal potential of purchased two lead compounds 
using standard microdilution method. 
In silico lead identification: Structural data files 
related to Fusicoccin, as a ligand for lead identification, 
C terminus of H
+
-ATPase and 14-3-3 regulatory protein 
are available through online data banks (1o9F.pdb file). 
The functional part of the ligand, Fusicoccin that comes 
into interactions between C end of ATPase and binding 
moiety of 14-3-3 protein was introduced in the study of 
Martin Wurtele
12
. To identify candidate therapeutics, we 
performed computational screening of a virtual 3D 
database of drug-like molecules. Also, we tested 
computationally selected small molecules, which 
resemble the functional part of the ligand performing 
ligand docking or geometry optimization, using Argus 
Lab application (4.0.1). Several small molecules, as lead 
compounds, were identified; however, the two 
molecules that showed higher ligation scores and were 
commercially available were selected and purchased. 
Antifungal bioassay: Standard strains of Candida 
albicans (ATCC10231), as a pathogen yeast, and 
Saccharomyces cerevisiae (PTCC 5052), as a 
nonpathogenic yeast, were applied to evaluate antifungal 
potential of the two identified lead compounds using micro-
well plate dilution assay based upon the NCCLS reference 
method. The two lead compounds included 4-phenyl butyric 
acid (PBA, Merck: 820986) and 3-Cyclohexan propionic acid 
(CXP, Merck: 818673). Malt Extract Broth (Oxoid) was used 
to subculture the yeasts and for serial dilutions. DMSO was 
used as solvent for dissolving the compounds. Minimum 
inhibitory concentrations (MIC) were carried out by using 
serial dilution technique in 96 well microtiter plates. The 
yeasts were subcultured in MEB media at 35°C for 24 h. 
Prior to inoculation, the yeast strains were adjusted to 0.5 
McFarland standards turbidity and diluted 1:1000 in MEB. 
The two lead compounds were first diluted in DMSO to the 
highest concentration of 10 mg/ml. Moreover, the 
concentration of 3.2 mg/ml of the antifungal agent 
amphotericin B (Sigma, Germany) in dimethyl sulfoxide was 
utilized as medium positive control. 
Two-fold serial dilutions of the leads were produced in the 
eight consecutive wells. One hundred μl of yeast suspensions 
were added to 100 μl of diluted compound for all wells. The 
plates were incubated at 30°C for 48 h and assessed by a light 
microscope. All the tests were done in broth and repeated 
three times in separate testing. Addition of culture media and 
inoculum to the wells of these plates diluted the final tested 
compounds and amphotericin B concentrations at 1000 - 1.9 
and 32 - 0.06 µg/ml, respectively. Microdilution trays were 
thereafter incubated at 35°C and examined after 24-48 hr to 
determine MIC (Minimum inhibitory concentration) and 
MFC (Minimum fungicidal concentration) values. It is worth 
noting that the MIC was defined as the lowest concentration 
of the compounds to inhibit the growth of yeast. Minimum 
Figure 1. Fusicoccin structure 
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fungicidal concentration (MFC) was determined by plating 
samples from clear wells onto Malt Extract Agar. More to 
the point, MFC was defined as the lowest concentration 
yielding negative subculture.  
Results 
The best ligation scores obtained from ArgusLab 
pertained to Cyclohexan propionic acid (-11.810379 
kcal/mol) and 4-phenyl butyric acid (-14.641133 
kcal/mol). The more characteristics of the two lead 
compounds identified through in silico screening 
methods are illustrated in table 1. Antifungal activities 
of the two compounds were compared with Miconazole 
and are shown in table 2. Our results showed that C. 
albicans (ATCC10231) and S. cerevisiae (PTCC 5052) 
isolates were partly susceptible to these compounds. 
Two lead compounds, cyclohexane propionic acid and 
4-phenyl butyric acid, exerted antifungal properties in 
low concentrations. This makes these molecules suitable 
candidates for further optimization. The MIC and MFC 
obtained for the two compounds are depicted in table 2. 
 
 
Table 1: Characteristics of the two identified lead compounds 
Chemical Structure Molecular Formula Name & Cat. No. 
 C9H16O2 3-Cyclohexan propionic acid (CXP)  
Merck: 818673 
Drug bank ID: DB02242 
PDB entry: 2ay2 
CAS Number: 701-97-3 
 C10H12O2 4-phenyl butyric acid (PBA) 
Merck: 820986 
CAS Number: 1821-12-1 
The scores calculated by the Argus Lab application for the compounds were as follows: 
Cyclohexan propionic acid:  -11.810379 kcal/mol 
4-phenyl butyric acid:       -14.641133 kcal/mol 
Table 2: MIC (µg/ml) and MFC (µg/ml) calculated for the two leads 
 S. cerevisiae Candida albicans 
Drug    MIC*   MIC* MFC* MIC* MFC* 
CXP 50 150 100 200 
PBA 100 200 100 250 
Miconazole 1.5 1.5 2 2.5 
 
* Results obtained from 48 h broth cultures 
Highly-susceptible: MICs < 8 µg/ml  
Susceptible: 8< MICs <100 µg/ml  
Semi-susceptible: MICs 100< MICs< 1000 µg/ml 
Discussion 
Fungi are important agent for human disease. The 
increasing incidence of opportunistic fungal infections 
and the limited number of existing antifungal drugs and 
the emergence of drug resistance in fungal pathogens 
make serious health problems owing to an augmented 
incidence of treatment failures. Yeast species, which are 
the most crucial fungal pathogens, belong to the genus 
Candida. These species can cause a wide range of human 
diseases, namely life-threatening invasive infections in 
immunocompromised individuals. Candida albicans 
exists as a normal flora on the mucus membranes and in 
the intestinal tract of some healthy individuals; 
nevertheless, it is frequently found in certain patients and 
may result in serious opportunistic infections. 
Furthermore, Saccharomyces cerevisiae is nonpathogenic 
yeast. Both species of candida albicans and 
Saccharomyces cerevisiae have membrane-bound H
+
-







-ATPases produce a chemiosmotic 
H
+
-gradient across the plant plasma membrane. This 
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gradient is used to drive solute uptake through H
+
-
coupled transporters. The proton gradient generated by 
the pump energizes many important transport systems of 
the cells
17
. Yeast plasma membrane ATPase is 
fundamental for growth 
18
. Therefore, any amino acid 
replacements that fail functionality of yeast H
+
-ATPases 
are associated with lethality 
7
. Plant and animal cells use 
entirely different ion pumps. For instance, plants use an 
H
+




-ATPase to energize the 
plasma membrane with an electrochemical gradient
17
. In 
spite of animal cells using Na
+ 
ions, protons are 
exclusively used as the coupling ion in plant cells
5
. It 
was demonstrated that the amino acid sequence of the 
plant H
+
-ATPase is more closely related to fungi and 
protozoan H
+













. The necessity of 
membrane H
+
-ATPase for yeast cell growth and 
distinction of the pump between yeast and animal cells 
makes the molecule a promising target for drug design. 
Computer modeling has recently been used to discover 
and design new pharmaceuticals. A number of easy 
accessible species specific genomic, proteomic and 
metabolomics database have been established to offer 
novel and clinically important targets for screening. For 
lead identification, structural and functional information 
concerning target molecule and the nature of its 
interaction with known ligand is used. Virtual screening 
adopts an alternative approach and applies computer-
based methods to screen large chemical libraries targeted 
on a biological receptor. Such a task is greatly facilitated 
by the advent of high performance computing 
environments, data management software and the 
internet to take the advantage of delivering new drug 
candidates more quickly and with lower costs
20,21
. The 
major roles of computation in drug discovery are virtual 
screening and de novo design, evaluation of drug 
likeness, and advanced methods for determining protein-
ligand binding
22,23
. In the current study, two lead 
compounds were identified and used for targeting the 
pumps. Our findings indicate that stable activation of the 
membrane H+-ATPase by the compounds in candida 
albicans and Saccharomyces cerevisiae is accompanied 
by the cell death. The results from the present study 
indicate that the two identified lead compounds, 
cyclohexane propionic acid and 4-phenyl butyric acid, 
act potentially against yeast cells and demonstrate proper 
potentials for further optimization to fulfill the needs for 
safe and effective drug design. 
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